Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086233 | 0.90 | GPR119 (0.52) | USP30GPR119SCN9ACHEK2HDAC1 | |
| SCHEMBL3983980 | 0.88 | USP30 (0.46) | USP30HPGDSGPR119KDM4EPKM | |
| SCHEMBL3984528 | 0.86 | GPR119 (0.49) | USP30HPGDSGPR119CCNT1HDAC1 | |
| SCHEMBL3984556 | 0.86 | KDM1A (0.47) | HPGDSKDM1A | |
| SCHEMBL1347367 | 0.83 | KDM1A (0.47) | HPGDSKDM1A | |
| SCHEMBL1346051 | 0.83 | KDM1A (0.47) | HPGDSKDM1A | |
| SCHEMBL1346050 | 0.83 | KDM1A (0.47) | HPGDSKDM1A | |
| SCHEMBL1348274 | 0.81 | KDM1A (0.49) | HPGDSKDM1A | |
| SCHEMBL4097506 | 0.81 | GPR119 (0.57) | USP30GPR119HDAC1 | |
| SCHEMBL3987089 | 0.80 | GPR119 (0.59) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | USP30 3721/4885HPGDS 2571/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.